Is rosuvastatin 5 mg safe to take
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that rosuvastatin 5 mg is safe and well-tolerated for reducing LDL-C and total cholesterol levels in various patient populations.
Consensus Meter
9 papers analyzed
Yes - 100%
Possibly - 0%
No - 0%
Research summarized with Copilot
Beta20 papers analyzed
Safety of Rosuvastatin 5 mg: A Comprehensive Review
Introduction to Rosuvastatin Safety
Rosuvastatin, a widely used statin, is prescribed to manage hypercholesterolemia and reduce cardiovascular risk. The safety profile of rosuvastatin, particularly at the 5 mg dose, has been extensively studied across various populations and clinical settings. This article synthesizes findings from multiple studies to provide a clear understanding of the safety of rosuvastatin 5 mg.
Adverse Events and Tolerability
General Safety Profile
In a large multinational clinical trial program involving 16,876 patients, rosuvastatin 5-40 mg was found to have an adverse event profile similar to other statins like atorvastatin, simvastatin, and pravastatin. The incidence of adverse events was comparable between patients taking rosuvastatin and those on placebo, indicating a favorable safety profile.
Specific Adverse Events
Clinically significant elevations in liver enzymes and creatine kinase were rare, occurring in less than 0.2% and 0.3% of patients, respectively. Myopathy was also infrequent, with an occurrence rate of 0.03% at doses up to 40 mg. Importantly, no deaths were attributed to rosuvastatin in the study, and the development of proteinuria was not predictive of renal disease.
Comparative Safety with Other Statins
Efficacy and Safety in Different Populations
Rosuvastatin 5 mg has been shown to be more effective at reducing LDL-C and total cholesterol levels compared to atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, while maintaining a similar safety profile. This dose allows more patients to achieve their LDL-C goals, providing an additional dosing option for those at lower cardiovascular risk or with a higher potential for developing myopathy.
Studies in Specific Populations
In Japanese patients with hypercholesterolemia, rosuvastatin 5 mg was more effective than atorvastatin 10 mg in achieving LDL-C goals and improving fasting plasma glucose levels, with both drugs being well tolerated. Similarly, in Chinese patients, rosuvastatin 5 mg demonstrated non-inferiority to atorvastatin 10 mg in lowering LDL-C, with a comparable rate of adverse events.
Safety in Special Populations
Children and Adolescents
In children and adolescents with familial hypercholesterolemia, rosuvastatin 5 mg was well tolerated and significantly reduced LDL-C levels. The treatment did not adversely affect growth or sexual maturation, and most adverse events were mild .
Patients Intolerant to Other Statins
For patients unable to tolerate other statins due to myalgia, rosuvastatin 5 mg was found to be well tolerated and effective in reducing LDL-C levels. Only one patient discontinued treatment due to muscle pain, and no significant liver enzyme or creatine kinase elevations were observed.
Conclusion
Rosuvastatin 5 mg is generally safe and well tolerated across various patient populations, including those with hypercholesterolemia, familial hypercholesterolemia, and those intolerant to other statins. Its safety profile is comparable to other commonly used statins, making it a viable option for managing cholesterol levels and reducing cardiovascular risk.
Sources and full results
Most relevant research papers on this topic
